Investigators are studying samples from a group of 100 patients to try to lock down patterns in circulating tumor DNA that can be used to validate monitoring methods for the clinic.
The team demonstrated that the approach can yield high sensitivity while maintaining near-perfect specificity, but it must now replicate the early results in a much larger study.
